About Peakdale
Peakdale is a Healthcare company based in High Peak (United Kingdom) founded in 1992, and was acquired by Concept Life Sciences in July 2014. Integrated drug discovery and medicinal chemistry services. Peakdale has raised $3.77 million across 2 funding rounds from investors including Concept Life Sciences and Solon Ventures. Peakdale offers products and services including Integrated Drug Discovery, Assay Development, Synthetic Chemistry, In vitro ADME Assays, and Toxicology Testing. Its focus areas include Biopharma Outsourcing, CRO and Drug Discovery. Its legal entity is CONCEPT LIFE SCIENCES LIMITED. Its competitors include CatSci and Domainex; 2 of its 2 listed competitors have raised funding.
Company details
Peakdale Molecular a contract research organisation, provides drug discovery services to pharmaceutical, biotechnology, diagnostics, and materials sciences industries. It offers drug discovery support services, including in vitro ADMET, medicinal and computational chemistry, and parallel array services; nucleoside chemistry that include nucleoside and nucleotide services; and materials chemistry services in the areas of printable electronics, nanomaterials, performance lubricants, and fuel additives. The company also offers research support services, such as process research and development, analytical services, purification, pressure chemistry, hydrogenation, and catalogue collection; custom synthesis; contract research; and synthesis and reaction screening services that optimise reagents, catalyst loading, or reaction time. In addition, it offers intermediates for pharmaceutical research; and compounds for amino acid synthesis. Peakdale is able to contribute to the early drug discovery process with the capability to use its compound collection or custom designed sets of compounds to generate a hit, medicinal chemistry optimisation capabilities and scale up facilities to aid a customer in a research programme spanning the drug discovery process from hit generation to Phase I clinical studies.
- Headquarters High Peak, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website peakdale.co.uk
- Social LinkedIn X
- Acquired by Concept Life Sciences (Jul 2014)
- Legal Name Concept Life Sciences Limited
- Date of Incorporation 02 Jun, 2014
- Jurisdiction CHAPEL-EN-LE-FRITH, HIGH PEAK, ENGLAND
- Total Equity Funding$3.77M (USD)
in 2 rounds
- Latest Funding Round$1.97M (USD), Series A
Jan 2008
- InvestorsConcept Life Sciences
& 1 more
- Acquired byConcept Life Sciences
(Jul 2014)
Products & Services of Peakdale
Peakdale offers a comprehensive portfolio of products and services, including Integrated Drug Discovery, Assay Development, Synthetic Chemistry, In vitro ADME Assays, and Toxicology Testing.
Services for target validation and hit identification in drug research
Techniques for cell-based assays and biophysical characterization
Computer-aided and medicinal chemistry for drug synthesis
Testing for absorption, distribution, metabolism, and excretion
Evaluations for cytotoxicity and hepatotoxicity in drug development
Funding Insights of Peakdale
Peakdale has successfully raised a total of $3.77M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $1.97 million completed in January 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.77M
- Total Rounds 2
- Last Round Series A — $1.97M
- First Round $1.8M
(Sep 2004)
- Investors Count 1
All 2 funding rounds of Peakdale with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2008 | $1.97M | Series A | – | – | |
| Sep 2004 | $1.8M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in Peakdale
Peakdale has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Concept Life Sciences and Solon Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech and Offline focused Stage-Agnostic micro VC Firm investing in the UK | solonventures.com | London, United Kingdom | ||
International laboratory testing and consultancy in life sciences are offered. | 2014 | conceptlifesciences.com | Manchester, United Kingdom |
Investor details for Peakdale
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Peakdale
4 dated milestones of Peakdale across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Peakdale is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Series A, of $2.0M.
- Exit Acquired by Concept Life Sciences.
Competitors of Peakdale
Peakdale has 2 listed competitors in our database, 2 of them funded. They include CatSci and Domainex.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| catsci.com | 2010 | Cardiff, United Kingdom | $5.89M | 63 | Drug discovery services are provided to pharmaceutical clients worldwide. | |
| domainex.co.uk | 2001 | Cambridge, United Kingdom | $4.97M | 93 | Drug discovery CRO company for epigenetic research and inflammatory diseases |
Detailed competitors of Peakdale
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Peakdale
Peakdale was founded in 1992 and raised its 1st funding round 12 years after it was founded.
Peakdale is headquartered in High Peak, United Kingdom. It is registered at High Peak, Derbyshire, United Kingdom.
Peakdale is a funded company, having raised a total of $3.77M across 2 funding rounds to date. The company's 1st funding round was a Series A of $1.8M, raised on Sep 2004.
Peakdale Molecular a contract research organisation, provides drug discovery services to pharmaceutical, biotechnology, diagnostics, and materials sciences industries. It offers drug discovery support services, including in vitro ADMET, medicinal and computational chemistry, and parallel array services; nucleoside chemistry that include nucleoside and nucleotide services; and materials chemistry services in the areas of printable electronics, nanomaterials, performance lubricants, and fuel additives. The company also offers research support services, such as process research and development, analytical services, purification, pressure chemistry, hydrogenation, and catalogue collection; custom synthesis; contract research; and synthesis and reaction screening services that optimise reagents, catalyst loading, or reaction time. In addition, it offers intermediates for pharmaceutical research; and compounds for amino acid synthesis. Peakdale is able to contribute to the early drug discovery process with the capability to use its compound collection or custom designed sets of compounds to generate a hit, medicinal chemistry optimisation capabilities and scale up facilities to aid a customer in a research programme spanning the drug discovery process from hit generation to Phase I clinical studies.
Peakdale offers Integrated Drug Discovery, Assay Development, Synthetic Chemistry, In vitro ADME Assays, and Toxicology Testing.
Peakdale has 2 investors. Key investors include Concept Life Sciences, and Solon Ventures.
Peakdale operates through Concept Life Sciences Limited.
Yes. Peakdale was acquired by Concept Life Sciences in July 2014.